Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving ...
The TNF-alpha inhibitor is indicated to treat children weighing at least 15 kg living with moderately to severely active ...
A first-in-class clinical trial will initiate this quarter to determine if a checkpoint agonist can down-regulate activated T cells to help reduce inflammation and tissue damage in patients with ...
Clinical Trials Arena on MSN
J&J and Protagonist’s UC pill goes to Phase III after mid-stage success
Analysts note icotrokinra could be a competitive player in the UC market if it were to be approved due to its oral ...
The FDA has approved golimumab for the treatment of children with moderately to severely active ulcerative colitis who weigh ...
Johnson & Johnson's Simponi gains FDA approval for treating pediatric ulcerative colitis, expanding options for young patients with this chronic condition.
Johnson & Johnson announced additional Week 12 results from the Phase 2b ANTHEM-UC study of icotrokinra, a first-in-class investigational targeted ...
FDA approves Johnson & Johnson's Simponi for children with moderate to severe ulcerative colitis, supported by positive Phase ...
Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated with the highest dose achieving endoscopic improvement ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback